Alliance Pharma Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	178.84	180.68	167.42	163.21	129.8
Revenue Growth (YoY)	-1.02%	7.92%	2.58%	25.74%	-4.30%
Cost of Revenue	69.55	75.66	65.73	53.76	46.99
Gross Profit	109.29	105.02	101.68	109.45	82.82
Selling, General & Admin	70.41	52.47	63.96	60.2	44.61
Operating Expenses	80.43	62.46	73.25	70.98	53.14
Operating Income	28.85	42.56	28.43	38.47	29.67
Interest Expense	-8.95	-9.99	-5.43	-3.65	-2.66
Interest & Investment Income	0.06	0.11	0.02	0.02	0.01
Currency Exchange Gain (Loss)	0.78	-0.48	0.06	0.21	-0.65
Other Non Operating Income (Expenses)	-0.28	-	-	-	-
EBT Excluding Unusual Items	20.47	32.21	23.07	35.05	26.37
Merger & Restructuring Charges	-	-	-	-2.84	-1.3
Impairment of Goodwill	-1.69	-	-18.78	-	-1.14
Gain (Loss) on Sale of Assets	2.03	-	-	-	-
Asset Writedown	-34.83	-79.25	-27.71	-6.15	-10.91
Other Unusual Items	-0.44	-1.75	0.37	-7.9	-
Pretax Income	-14.46	-48.8	-23.05	18.16	13.02
Income Tax Expense	-3.73	-15.66	-1.84	10.84	4.99
Net Income	-10.73	-33.14	-21.21	7.32	8.03
Net Income to Common	-10.73	-33.14	-21.21	7.32	8.03
Net Income Growth	-	-	-	-8.82%	-67.91%
Shares Outstanding (Basic)	540	540	539	535	531
Shares Outstanding (Diluted)	540	540	539	542	537
Shares Change (YoY)	0.06%	0.12%	-0.53%	0.93%	1.35%
EPS (Basic)	-0.02	-0.06	-0.04	0.01	0.02
EPS (Diluted)	-0.02	-0.06	-0.04	0.01	0.01
EPS Growth	-	-	-	-9.40%	-68.43%
Free Cash Flow	37.88	30.71	20.61	37.13	36.96
Free Cash Flow Per Share	0.07	0.06	0.04	0.07	0.07
Dividend Per Share	-	-	0.018	0.017	0.016
Dividend Growth	-	-	5.03%	5.03%	200.37%
Gross Margin	61.11%	58.12%	60.74%	67.06%	63.80%
Operating Margin	16.13%	23.56%	16.98%	23.57%	22.86%
Profit Margin	-6.00%	-18.34%	-12.67%	4.48%	6.18%
Free Cash Flow Margin	21.18%	17.00%	12.31%	22.75%	28.47%
EBITDA	35.9	50.23	36.38	46.3	37.78
EBITDA Margin	20.08%	27.80%	21.73%	28.37%	29.11%
D&A For EBITDA	7.05	7.66	7.95	7.83	8.11
EBIT	28.85	42.56	28.43	38.47	29.67
EBIT Margin	16.13%	23.56%	16.98%	23.57%	22.86%
Effective Tax Rate	-	-	-	59.69%	38.33%

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.